Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease.

Results: There was a high statistically significant difference between IBD patients and controls in levels of hepcidin ( < 0.01). Namely, serum hepcidin levels were significantly higher in the control group. There was no statistically significant correlation of serum hepcidin with CRP, Mayo score, or CDAI, respectively ( > 0.05). However, we have found a statistically significant negative correlation of sTfR and TIBC with hepcidin ( < 0.01).

Conclusion: Results of our study suggest that hepcidin is a reliable marker of IDA in patients with IBD, and it could be used in routine clinical practice when determining adequate therapy in these patients.